2',3'-dideoxy-beta-5-fluorocytidine has been researched along with Acquired Immunodeficiency Syndrome in 1 studies
*Acquired Immunodeficiency Syndrome: An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Broder, S; Driscoll, JS; Kim, CH; Marquez, VE; Mitsuya, H | 1 |
1 other study(ies) available for 2',3'-dideoxy-beta-5-fluorocytidine and Acquired Immunodeficiency Syndrome
| Article | Year |
|---|---|
Potential anti-AIDS drugs. 2',3'-Dideoxycytidine analogues.
Topics: Acquired Immunodeficiency Syndrome; Cell Line; Chemical Phenomena; Chemistry; Deoxycytidine; HIV; Structure-Activity Relationship; T-Lymphocytes, Helper-Inducer; Zalcitabine | 1987 |